Zydus announces settlement with Aptalis on CANASA (mesalamine suppository, 1 g)

Zydus announces settlement with Aptalis on CANASA® (mesalamine suppository, 1 g) Ahmedabad, India, August 14, 2017 Cadila Healthcare Limited, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, today announced that the patent litigation relating to Aptalis’s CANASA® (mesalamine suppository, 1 g) has been settled. As a result of the settlement, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its gen eric version of CANASA ® in the United States beginning on June 13, 2019, or earlier under certain circumstances. Zydus Cadila previously received tentative approval from the USFDA to market its generic version of CANASA® (mesalamine suppository, 1 g). CANASA® is indicated to treat mildly to moderately active ulcerative colitis. Zydus Cadila’s generic product will be produced at the group’s Topical plant at Ahmedabad. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗